UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000042223
Receipt number R000047723
Scientific Title Clinical research of the health management support for long-term biliary atresia survivors -assessment of nutrition, microbiota, bile acid, metabolism and immune system associated with liver dysfunction and various drugs-
Date of disclosure of the study information 2020/10/23
Last modified on 2020/10/23 16:23:53

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical research of the health management support for long-term biliary atresia survivors -assessment of nutrition, microbiota, bile acid, metabolism and immune system associated with liver dysfunction and various drugs-

Acronym

Clinical research of the health management support for long-term biliary atresia survivors -assessment of nutrition, microbiota, bile acid, metabolism and immune system associated with liver dysfunction and various drugs-

Scientific Title

Clinical research of the health management support for long-term biliary atresia survivors -assessment of nutrition, microbiota, bile acid, metabolism and immune system associated with liver dysfunction and various drugs-

Scientific Title:Acronym

Clinical research of the health management support for long-term biliary atresia survivors -assessment of nutrition, microbiota, bile acid, metabolism and immune system associated with liver dysfunction and various drugs-

Region

Japan


Condition

Condition

Biliary atresia

Classification by specialty

Hepato-biliary-pancreatic medicine Surgery in general Hepato-biliary-pancreatic surgery
Pediatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To reveal the health problems of the long-term biliary atresia survivors by measuring bile acid, fatty acid, and microbiota.

Basic objectives2

Others

Basic objectives -Others

Contribute the healthy management support to the long-term biliary atresia survivors.

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Blood test (complete blood count, serum chemistry, bile acid, fatty acid) and stool analysis (microbiota, organic acid) are performed.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Maneuver

Interventions/Control_1

A blood sample is taken.

Interventions/Control_2

A stool sample is collected.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

1 days-old <=

Age-upper limit

40 years-old >

Gender

Male and Female

Key inclusion criteria

Subjects who were diagnosed biliary atresia and treated by Kasai portoenterostomy or liver transplantation.

Key exclusion criteria

Subjects who are deemed inappropriate to participate in this study by the principle investigator.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Yuichiro
Middle name
Last name Yamashiro

Organization

Juntendo University School of Medicine

Division name

Probiotics Research Laboratory

Zip code

113-8421

Address

2-1-1 Hongo, Bunkyo-ku, Tokyo

TEL

03-3813-3111

Email

yamashiro@juntendo.ac.jp


Public contact

Name of contact person

1st name Takanori
Middle name
Last name Ochi

Organization

Juntendo University School of Medicine

Division name

Department of Pediatric General and Urogenital Surgery

Zip code

113-8421

Address

2-1-1 Hongo, Bunkyo-ku, Tokyo

TEL

03-3813-3111

Homepage URL


Email

tochi@juntendo.ac.jp


Sponsor or person

Institute

Juntendo University

Institute

Department

Personal name



Funding Source

Organization

Yakult Honsha Co.,Ltd.

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Juntendo University School of Medicine

Address

2-1-1 Hongo, Bunkyo-ku, Tokyo

Tel

03-3813-3111

Email

yamashiro@juntendo.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 10 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2020 Year 09 Month 04 Day

Date of IRB

2020 Year 08 Month 24 Day

Anticipated trial start date

2020 Year 09 Month 04 Day

Last follow-up date

2022 Year 12 Month 25 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2020 Year 10 Month 23 Day

Last modified on

2020 Year 10 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047723


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name